ESTRO 2024 - Abstract Book

S5320

Radiobiology - Tumour biology

ESTRO 2024

radiotherapy with CD98hc-targeted UniCAR T immunotherapy showed a synergistic anti-tumor effect (2, 3). In vivo trial for targeting HNSCC tumors, including CSCs, using CD98hc-targeted UniCAR T cells in combination with radiochemotherapy is currently ongoing.

Conclusion:

These results indicate that the expression of CD98hc-AATs is associated with HNSCC CSC properties and is regulated by ALDH activity in CSCs. The interplay between ALDH1 and CD98hc-ATTs is essential for CSC survival and tumor regrowth after radiotherapy (Figure 1 A). Our study demonstrated that activating the CD98hc-AATs axis is a clinically relevant biomarker of HNSCC radioresistance and a potential target for HNSCC radiosensitization (Figure 1 B).

Keywords: Amio acid transporters, immunotherapy, HNSCC

References:

1. Digomann et al., Clin Cancer Res 2019.

2. Köseer et al., Cancers 2022.

3. Köseer et al., Cancers 2023.

244

Digital Poster

identification of ATM gene in radio-resistance pancreatic cancer cells using system biology analysis

Shiva Ghasemi 1 , Carsten Herskind 2 , Babak Boutorabi 3 , John Price 4 , Meysam Mobasheri 5 , Hamidreza Mirzaee 6